# NewLimit

> NewLimit is a South San Francisco biotechnology company developing experimental medicines that use transcription factors to restore youthful functions in old cells while preserving their identity. Its in-house discovery platform combines pooled genomic screening, functional assays, and machine learning. A liver-directed candidate is in preclinical development, with a first human trial planned for 2027.

- **Founded:** 2022
- **Headquarters:** South San Francisco, United States
- **Founders:** Jacob Kimmel (Co-founder and CEO), Brian Armstrong (Co-founder and board member), Blake Byers (Co-founder)
- **Products:** Liver reprogramming candidate, Discovery Engine, Ambrosia, Vascular and T-cell programs
- **Notable:** Identified transcription-factor sets in 2024 that restored youthful gene-expression signatures in T cells and hepatocytes while preserving cell-type programs., Reported preclinical liver payloads that improved resilience to alcohol-related damage and regeneration after injury in animal models., Reported a more than fivefold reduction in reagent construction cost and turnaround time and more than tenfold improvement in humanized-liver screening throughput per dollar during 2025.

## Products & services

- **Liver reprogramming candidate** — Preclinical LNP-mRNA therapeutic candidate designed to deliver transcription-factor payloads to old hepatocytes and restore resilience and regenerative function; first human trial planned for 2027.
- **Discovery Engine** — Internal platform for pooled transcription-factor screening, single-cell readouts, functional assays, humanized-liver experiments, and delivery optimization.
- **Ambrosia** — Internal machine-learning system that predicts the effects of transcription-factor combinations and prioritizes experiments across cell types.
- **Vascular and T-cell programs** — Preclinical programs investigating whether reprogramming can restore functions in endothelial and immune cells.

## Achievements

- Identified transcription-factor sets in 2024 that restored youthful gene-expression signatures in T cells and hepatocytes while preserving cell-type programs.
- Reported preclinical liver payloads that improved resilience to alcohol-related damage and regeneration after injury in animal models.
- Reported a more than fivefold reduction in reagent construction cost and turnaround time and more than tenfold improvement in humanized-liver screening throughput per dollar during 2025.
- Reported five endothelial payloads that improved youthful gene expression and regenerative function in old human cells in 2026.
- Scaled production of its lead asset more than 120-fold in 2026 and planned a first human trial for 2027.

## Latest updates

- **2026-07** — Reported 100-fold manufacturing scale of its lead asset, cross-cell-type AI models using about threefold less endothelial data, and five endothelial payloads with functional effects.
- **2026-06** — Announced a $435 million Series C and a plan to bring its first liver-directed reprogramming medicine into human trials in 2027.
- **2026-03** — Reported another hepatocyte payload improving both damage resilience and regeneration in preclinical models.

## Links

- Website: https://www.newlimit.com/
- LinkedIn: https://www.linkedin.com/company/newlimit/
- Twitter/X: https://twitter.com/newlimit

---

Profile page: https://yespress.io/newlimit
Published by YesPress — https://yespress.io
Last updated: 2026-09-29